In particular, the tumors undergo cell cycle arrest through cyclin-dependent kinase inhibitor 1C and forkhead box O1/insulin receptor substrate 2–orchestrated reprogramming of signaling.[47] The resulting quiescence slows the tumor proliferation rate. The gene discussed is IRS2; the disease is neoplasm.